Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Phillipe Guillaume"'
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 75:202-203
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e36eaf589d42738f2aa9485084ad1c06
https://doi.org/10.1016/j.vascn.2015.08.149
https://doi.org/10.1016/j.vascn.2015.08.149
Autor:
Yingzhe Yu, Markus Rojewski, Michael Schmitt, Bao An Chen, Mark Ringhoffer, Anita Schmitt, Phillipe Guillaume, V. RuBeler, Jinfei Chen, Jochen Greiner, Fei Fei, S. von Harsdorf, M. Gbtzz, X. Yu, H. Dbhner, Donald Bunjes
Publikováno v:
Journal of Cellular and Molecular Medicine
The novel selective BCR-ABL Breakpoint cluster region--Abelson murine leukemia viral oncogene homolog 1 (BCR-AML) inhibitor nilotinib (AMN107) is a tyrosine kinase inhibitor that is more potent against leukaemia cells in vitro than imatinib. As nilot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f8990839df8317fa1586d438d2fd6cb
https://pubmed.ncbi.nlm.nih.gov/19374687
https://pubmed.ncbi.nlm.nih.gov/19374687
Autor:
Hartmut Döhner, Li Li, Jochen Greiner, Michael Schmitt, Mark Ringhoffer, Gerd Ritter, Thomas F. E. Barth, Phillipe Guillaume, Markus Wiesneth, Krzysztof Giannopoulos
Publikováno v:
Blood. 106(3)
The receptor for hyaluronic acid–mediated motility (RHAMM/CD168) has been described as a leukemia-associated antigen. To define T-cell epitopes of RHAMM/CD168 toward specific immunotherapies for acute myeloid leukemia (AML), 10 potential HLA-A2–b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e28cc75ccdadb36d2112a31bb64363e
https://pubmed.ncbi.nlm.nih.gov/15827130
https://pubmed.ncbi.nlm.nih.gov/15827130
Autor:
Gerd Ritter, Anna Dmoszynska, Markus Rojewski, Anita Schmitt, Martin Bommer, Jinfei Chen, Jochen Greiner, Marlies Goetz, Marta Heyduk, Krzysztof Giannopoulos, Michael Schmitt, Phillipe Guillaume, Isabel Funk, Hartmut Döhner
Publikováno v:
Blood. 112:2911-2911
We have demonstrated immunological responses and positive clinical effects of a peptide vaccination for patients with AML, MDS, MM and CLL with a limited tumor load or a minimal residual disease over-expressing RHAMM using 300 μg RHAMM-R3 peptide (S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a7f965b2e21dce8e5afdf751bea8732
https://doi.org/10.1182/blood.v112.11.2911.2911
https://doi.org/10.1182/blood.v112.11.2911.2911
Autor:
Markus Rojewski, Sascha Gnjatic, Michael Schmitt, Li Li, Mark Ringhoffer, Anita Schmitt, Jinfei Chen, Peter Liebisch, Phillipe Guillaume, Krzysztof Giannopoulos, Hartmut Döhner, Jochen Jochen, Gerd Ritter
Publikováno v:
Blood. 108:409-409
Most patients with AML, MDS, MM and chronic lymphatic leukemia (CLL) express the receptor for hyaluronic acid mediated motility (RHAMM/CD168) on their tumor cells. We characterized RHAMM/CD168 as a leukemia-associated antigen (LAA) eliciting both hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77a07d88891e25f4dedf1d8357925cbf
https://doi.org/10.1182/blood.v108.11.409.409
https://doi.org/10.1182/blood.v108.11.409.409
Autor:
Li Li, Jinfei Chen, Mark Ringhoffer, Christiane Wendl, Michael Schmitt, Peter Liebisch, Jochen Greiner, Hartmut Doehner, Gerd Ritter, Phillipe Guillaume, Krzysztof Giannopoulos
Publikováno v:
Blood. 106:2781-2781
The receptor for hyaluronic acid mediated motility (RHAMM/CD168) has been described as a leukemia-associated antigen (LAA) eliciting both humoral and cellular immune responses in patients with hematological malignancies. RHAMM/CD168 is expressed in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8750851d72b4d3869d124d57888f2361
https://doi.org/10.1182/blood.v106.11.2781.2781
https://doi.org/10.1182/blood.v106.11.2781.2781